World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
59
Citations
13124
World Ranking
12487
National Ranking
5344

Overview

Robert C. Newton is affiliated with Incyte in the United States. Their research spans multiple disciplines within medicine and biochemistry, genetics, and molecular biology, with a primary focus on molecular biology, oncology, cancer research, immunology, and physiology.

The scientist has contributed extensively to several key topics, including:

  • NF-κB Signaling Pathways
  • Immune Response and Inflammation
  • Asthma and respiratory diseases
  • Cytokine Signaling Pathways and Interactions
  • Receptor Mechanisms and Signaling
  • Fibroblast Growth Factor Research
  • Estrogen and related hormone effects

Robert C. Newton has published research in various high-impact venues, notably:

  • The FASEB Journal
  • Journal of Pharmacology and Experimental Therapeutics
  • Journal of Biological Chemistry
  • Molecular Pharmacology
  • PLoS ONE

The following are examples of recent papers that illustrate the scope and focus of their research work:

  • Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib, 2020, Cancer Discovery
  • Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era, 2021, Journal of Biological Chemistry
  • Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy, 2020, Journal of Pharmacology and Experimental Therapeutics
  • Genomic determinants implicated in the glucocorticoid-mediated induction of KLF9 in pulmonary epithelial cells, 2020, Journal of Biological Chemistry
  • Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases, 2020, European Journal of Pharmacology

Frequent collaborators appearing in Robert C. Newton's published work include Mahmoud Mostafa, Akanksha Bansal, Anthony N. Gerber, Andrew Thorne, and Richard Leigh. These collaborations suggest a multidisciplinary approach integrating molecular biology, pharmacology, and immunology.

Best Publications

  • Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins.

    M. D. Tortorella;T. C. Burn;M. A. Pratta;I. Abbaszade

  • Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 + T cells directly within the tumor microenvironment

    Stefani Spranger;Holly K Koblish;Brendan Horton;Peggy A Scherle

  • Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

    Xiangdong Liu;Niu Shin;Holly K. Koblish;Gengjie Yang

  • Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.

    Ilgar Abbaszade;Rui-Qin Liu;Fude Yang;Stuart A. Rosenfeld

  • Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

    Jordan S. Fridman;Peggy A. Scherle;Robert Collins;Timothy C. Burn

  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

    Bin Bing S Zhou;Michael Peyton;Biao He;Changnian Liu

  • Aggrecan protects cartilage collagen from proteolytic cleavage.

    Michael A. Pratta;Wenqing Yao;Carl Decicco;Micky D. Tortorella

  • First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

    Gregory L. Beatty;Peter J. O'Dwyer;Jason Clark;Jack G. Shi

  • Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

    Alireza Eghtedar;Srdan Verstovsek;Zeev Estrov;Jan Burger

  • Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-α

    Robert C. Newton;Carl P. Decicco

  • Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

    Carrie M. Brodmerkel;Reid Huber;Maryanne Covington;Sharon Diamond

  • Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.

    Phillip C.C. Liu;Xiangdong Liu;Yanlong Li;Maryanne Covington

  • Regulation of monocyte integrin expression by beta-family chemokines.

    Krishna Vaddi;R. C. Newton

  • Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

    Xiangdong Liu;Robert C. Newton;Peggy A. Scherle

  • A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

    Xiangdong Liu;Qian Wang;Gengjie Yang;Cindy Marando

  • Targeting the c-MET signaling pathway for cancer therapy

    Xiangdong Liu;Wenqing Yao;Robert C Newton;Peggy A Scherle

  • Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).

    Micky D. Tortorella;Rui-Qin Liu;Timothy Burn;Robert C. Newton

  • Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.

    Ian M. Silverman;Antoine Hollebecque;Luc Friboulet;Sherry Owens

  • Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

    Jordan S. Fridman;Eian Caulder;Michael Hansbury;Xiangdong Liu

  • Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

    Percy H. Carter;Peggy A. Scherle;Jodi A. Muckelbauer;Matthew E. Voss

Frequent Co-Authors

Peggy Scherle
Peggy Scherle Incyte (United States)
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
George L. Trainor
George L. Trainor Bristol-Myers Squibb (Germany)
James W. Hodge
James W. Hodge National Institutes of Health
Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to diverse careers, many of which intersect with healthcare and advanced research. Pursuing an online degree can be a flexible way to gain specialized knowledge and skills. For those interested in management, the cahme accreditation for mha programs ensures quality training for aspiring healthcare administrators.

If you’re aiming for advanced clinical expertise, a doctor of nursing practice offers leadership roles for nurses, while some programs don’t require in-person clinicals. Those interested in high-level research or academic careers may consider an online phd in healthcare management, equipping graduates to solve complex problems in healthcare systems.

Additionally, the pharmaceutical industry is closely aligned with both biology and biochemistry. An online pharmd allows you to advance as a pharmacist or researcher in drug development. Each of these pathways offers unique opportunities for those inspired by the life sciences to shape the future of health and medicine.

Best Scientists Citing Robert C. Newton

Trending Scientists

Recently Published Articles